ClinicalTrials.gg
CompletedNCT07853196Updated Oct 6, 2026

Effects of Hyaluronic Acid Complex and Dexamethasone on Pain, Swelling, and Trismus After Mandibular Third Molar Surgery

An interventional study of Hyaluronic Acid Complex and Dexamethasone in Postoperative Morbidity, sponsored by Cyprus Health and Social Sciences University. Completed at 1 site in Cyprus. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Cyprus Health and Social Sciences University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2026, registered Sep 2026).
Updated Oct 6, 2026Eligibility revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 149 studies testing dexamethasone in Pain, Postoperative — 27 open to participants now, 31 under way, 2 of them phase 3. Dexamethasone · Pain, Postoperative.

Enrollment
131st of 149
45 · median 88
Started
2026
with 16 others
No phase
38 of 149
7 open now
Registered
146th of 149
by date

Among the 149 studies testing dexamethasone in Pain, Postoperative, this one is the 131st largest by enrollment, is one of 17 that started in 2026, is one of 38 with no phase, and was the 146th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

27 of the 149 studies testing dexamethasone in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

22 more — sign in →

By country, each count listing its studies:

All 27 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies testing dexamethasone in Pain, Postoperative, or all of them as a file.
02

Study summary

This study aimed to comparatively evaluate the effects of a hyaluronic acid complex and dexamethasone on postoperative pain, swelling, and trismus following mandibular third molar surgery, compared with a control group. Participants were evaluated in three groups: a hyaluronic acid complex group, a dexamethasone group, and a control group. Postoperative pain, facial swelling, and limitation of mouth opening were assessed during the postoperative follow-up period to compare postoperative outcomes among the groups.

03

Conditions studied

  • Postoperative Morbidity

Keywords

  • Mandibular Third Molar Surgery
  • Dexamethasone
  • Postoperative Pain
  • Facial Swelling
  • Trismus
  • Hyaluronic Acid
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 35 years.
  • No systemic disease.
  • No regular medication use.
  • Non-smoker.
  • Not pregnant or lactating.
  • Presence of an asymptomatic partially impacted mandibular third molar indicated for prophylactic surgical extraction.

Exclusion criteria

Exclusion Criteria:

  • Presence of acute pericoronitis.
  • Presence of an abscess or acute odontogenic infection.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    Control Group

    Following mandibular third molar extraction, SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge (MS0005; 1 × 1 × 1 cm; Ethicon, Johnson \& Johnson) was placed into the extraction socket. No hyaluronic acid complex or dexamethasone was administered. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.

    Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)

  • Experimental
    Hyaluronic Acid Complex Group

    Following mandibular third molar extraction, 0.2 mL of Monovisc® (22 mg/mL cross-linked high-molecular-weight sodium hyaluronate; Anika Therapeutics, Inc., Bedford, MA, USA), corresponding to 4.4 mg of sodium hyaluronate, was applied directly into the extraction socket. SPONGOSTAN™ Dental was subsequently placed to enhance retention within the socket. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.

    Drug: Hyaluronic Acid Complex · Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)

  • Experimental
    Dexamethasone Group

    Following mandibular third molar extraction, 1.5 mL of DEKORT® 8 mg/2 mL I.M./I.V. solution for injection (DEVA Holding A.Ş., Türkiye), corresponding to 6 mg of dexamethasone, was absorbed into SPONGOSTAN™ Dental and placed into the extraction socket. The surgical site was primarily closed with 3/0 silk sutures, which were removed on postoperative day 7.

    Drug: Dexamethasone · Device: Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)

Interventions

  • DrugHyaluronic Acid Complex

    Monovisc® (Anika Therapeutics, Inc., Bedford, MA, USA), containing 22 mg/mL cross-linked, high-molecular-weight sodium hyaluronate, was used. A 0.2 mL volume of the preparation (equivalent to 4.4 mg sodium hyaluronate) was applied directly into the extraction socket using a sterile applicator. SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge was subsequently placed into the socket to enhance retention of the preparation.

  • DEKORT® 8 mg/2 mL solution for I.M./I.V. injection (DEVA Holding A.Ş., Türkiye) was used. A 1.5 mL volume of the solution, corresponding to 6 mg dexamethasone, was absorbed into a SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge and placed directly into the extraction socket.

  • DeviceAbsorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)

    SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge (MS0005; 1 × 1 × 1 cm; Ethicon, Johnson \& Johnson) was placed directly into the extraction socket. In the control group, the gelatin sponge was used without hyaluronic acid or dexamethasone.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Assessed Using the Visual Analog Scale (VAS)

    Postoperative pain was assessed using a patient-reported Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicated no pain and 10 indicated unbearable/worst pain. Participants indicated their perceived pain intensity on the scale. No preoperative VAS measurement was performed

    Time frame: Postoperative days 1, 2, 3, and 7

  2. Facial Swelling Assessed Using Facial Measurements

    Facial swelling was assessed in millimeters (mm) using a flexible measuring tape. Three anatomical distances were measured: tragus to labial commissure, tragus to pogonion, and mandibular angle to lateral canthus. The arithmetic mean of the three measurements was calculated for each participant. Postoperative percentage change from the preoperative baseline was calculated as \[(postoperative mean - preoperative mean) / \|preoperative mean\|\] × 100. Positive values indicated an increase in facial measurements.

    Time frame: Preoperatively and on postoperative days 1, 2, 3, and 7

  3. Trismus Assessed by Maximum Interincisal Mouth Opening

    Trismus was assessed by measuring maximum interincisal mouth opening in millimeters (mm) using a digital caliper. The distance between the incisal edges of the maxillary and mandibular central incisors was measured once at each assessment. Postoperative percentage change from the preoperative baseline was calculated as \[(postoperative value - preoperative value) / \|preoperative value\|\] × 100. Negative values indicated a reduction in maximum mouth opening.

    Time frame: Preoperatively and on postoperative days 1, 2, 3, and 7

07

Study locations

1 site
  • NEW Cyprus Health and Social Sciences University
    Mórfou, Guzelyurt 99750, Cyprus
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared, as no IPD sharing plan was established for this study.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jul 2026, 4 months.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 1, 2026
StartActual
Mar 5, 2026
Primary completionActual
Jul 25, 2026
CompletionActual
Jul 25, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 5 added; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedAge between 18 and 35 years.
  • AddedNo systemic disease.
  • AddedNo regular medication use.
  • AddedNon-smoker.
  • AddedNot pregnant or lactating.
  • EditedInclusion Criteria:Age between 18 and 35 years. No systemic disease. No regular medication use. Non-smoker. Not pregnant or lactating. Presence of an asymptomatic partially impacted or fully impacted mandibular third molar indicated for prophylactic surgical extraction.
Exclusion criteria
  • AddedPresence of acute pericoronitis.
  • EditedExclusion Criteria:Presence of acute pericoronitis. Presence of an abscess or acute odontogenic infection.
Oct 6, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 6, 2026
    Eligibility 1 inclusion criterion edited, 5 added; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedAge between 18 and 35 years.
    • AddedNo systemic disease.
    • AddedNo regular medication use.
    • AddedNon-smoker.
    • AddedNot pregnant or lactating.
    • EditedInclusion Criteria:Age between 18 and 35 years. No systemic disease. No regular medication use. Non-smoker. Not pregnant or lactating. Presence of an asymptomatic partially impacted or fully impacted mandibular third molar indicated for prophylactic surgical extraction.
    Exclusion criteria
    • AddedPresence of acute pericoronitis.
    • EditedExclusion Criteria:Presence of acute pericoronitis. Presence of an abscess or acute odontogenic infection.
    + 3 other changes: index terms, verification date and conditions
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853196
Lead sponsor
Cyprus Health and Social Sciences University
Responsible party
Kadriye Yıldırım (Research Assistant/PhD Student, Cyprus Health and Social Sciences University) — Principal investigator
First posted
Oct 1, 2026
Start date
Mar 5, 2026
Primary completion
Jul 25, 2026
Completion
Jul 25, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion